JPRN-UMIN000021136已完成3 期
A phase III study of Platinum doublet chemotherapy with or without Nivolumab for the patients with chemo-naive, advanced non-small cell lung cancer (WJOG8615L) - A phase III study of Platinum doublet chemotherapy +/- Nivolumab in advanced non-small cell lung cancer (WJOG8615L)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects with active, known or suspected autoimmune disease. 2. Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization 3. Subjects with interstitial lung disease 4. Positive test for hepatitis B virus antigen or hepatitis C virus indicating acute or chronic infection
研究者
相似试验
进行中（未招募）
1 期
Platinum-doublet chemotherapy combined with nivolumab as first treatment for unresectable, locally advanced or metastatic neuroendocrine neoplasms of the stomach, intestines or pancreas or of unknown origin.EUCTR2019-001546-18-ESGrupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)38
进行中（未招募）
1 期
Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the CervixMetastatic (stage IVB), Persistent, or Recurrent Carcinoma of the CervixMedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000367-83-SEGrupo Español de Investigación en Cáncer de Ovario (GEICO)404
进行中（未招募）
1 期
Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the CervixMetastatic (stage IVB), Persistent, or Recurrent Carcinoma of the CervixMedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000367-83-NOGrupo Español de Investigación en Cáncer de Ovario (GEICO)404
进行中（未招募）
3 期
Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the CervixMetastatic (stage IVB), Persistent, or Recurrent Carcinoma of the CervixJPRN-jRCT2041190037Takekuma Munetaka56
招募中
3 期
Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervix2024-514179-17-00Grupo Espanol De Investigacion En Cancer De Ovario339